WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012054724) METHODS OF TREATING SEIZURE DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/054724    International Application No.:    PCT/US2011/057099
Publication Date: 26.04.2012 International Filing Date: 20.10.2011
IPC:
A61K 31/366 (2006.01), A61P 25/08 (2006.01), A61P 25/00 (2006.01)
Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue Cambridge, MA 02139-4307 (US) (For All Designated States Except US).
BEAR, Mark, F. [US/US]; (US) (For US Only).
OSTERWEIL, Emily [US/US]; (US) (For US Only)
Inventors: BEAR, Mark, F.; (US).
OSTERWEIL, Emily; (US)
Agent: MURRAY, Mary, K.; Hamilton, Brook, Smith & Reynolds, P.C. 530 Virginia Rd, P.O. Box 9133 Concord, MA 01742-9133 (US)
Priority Data:
61/405,446 21.10.2010 US
Title (EN) METHODS OF TREATING SEIZURE DISORDERS
(FR) MÉTHODES DE TRAITEMENT DE TROUBLES ÉPILEPTIQUES
Abstract: front page image
(EN)Seizure disorders are treated by Ras inhibitors. In an embodiment, the Ras inhibitor includes a farnesyl transferase inhibitor. In another embodiment, the farnesyl transferase inhibitor includes a 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor. In another embodiment, the 3-hydroxy-3-methylglutaryl- Coenzyme A reductase inhibitor is not a Ras inhibitor. Subjects having fragile X syndrome, autism, Angelman syndrome, Costello syndrome, cardio facio cutaneous syndrome, neurofibromatosis type I, Noonan syndrome and Coffm-Lowry syndrome that have seizure disorders can be treated.
(FR)Les troubles épileptiques sont traités par des inhibiteurs de Ras. Dans un mode de réalisation, l'inhibiteur de Ras comprend un inhibiteur de farnésyl transférase. Dans un autre mode de réalisation, l'inhibiteur de farnésyl transférase comprend un inhibiteur de 3-hydroxy-3-méthylglutaryl-coenzyme A réductase. Dans un autre mode de réalisation, l'inhibiteur de 3-hydroxy-3-méthylglutaryl-Coenzyme A réductase n'est pas un inhibiteur de Ras. Des sujets atteints du syndrome de l'X fragile, d'autisme, du syndrome d'Angelman, du syndrome de Costello, du syndrome cardio-facio-cutané, d'une neurofibromatose de type I, du syndrome de Noonan et du syndrome de Coffin-Lowry, qui présentent des troubles épileptiques, peuvent être traités.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)